(via NewsDirect)

Proactive Research Analyst Daniel Appiah gives the highlights from his latest research note on UK-based medical device company Creo Medical Group PLC (AIM:CREO). Creo recently announced that the medical device company's Speedboat Inject product was used for the first time in an upper gastrointestinal (GI) procedure in Europe, a major milestone for the business. Appiah says Creo is "looking very well" and gives his take on what recent developments are likely to mean for the company's financials.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

Copyright (c) 2023 TheNewswire - All rights reserved.

Copyright (c) 2023 TheNewswire - All rights reserved., source Press Releases